Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
| Autor: | Badar, Talha, Kantarjian, Hagop M., Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Cortes, Jorge E., Pemmaraju, Naveen, Pierce, Sherry R., Newberry, Kate J., Daver, Naval, Verstovsek, Srdan |
|---|---|
| Zdroj: | In Leukemia Research September 2015 39(9):950-956 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect